Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results - Full Text View

Purpose

RATIONALE: Examining biomarkers in abnormal cervical cells may improve the ability to detect these cells and plan effective treatment.

PURPOSE: Diagnostic trial to detect specific biomarkers in abnormal cervical cells in women who have abnormal Pap test results.

Condition	Intervention
Cervical Cancer	Procedure: Papanicolaou test Procedure: colposcopic biopsy Procedure: cytology specimen collection procedure Procedure: fluorescent antibody technique Procedure: study of high risk factors

MedlinePlus related topics:

Cancer Cervical Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Screening

Official Title:	Development of Antibody-Based Diagnostic Markers for Abnormal Cervical Cells

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

August 1999

Detailed Description:

OBJECTIVES: I. Compare the detection of transferrin receptor, epidermal growth factor receptor, and the MaTu-MN protein in exfoliated cervical epithelial cells from women with abnormal Pap test using fluorescent labeled antibody probe vs histology.

OUTLINE: Patients undergo a Pap test and a colposcopy. Cervical epithelial cells are collected from the most abnormal appearing lesion. Cells are examined for molecular markers using a fluorescent antibody test. The presence or absence of these markers is compared to results of the Pap test and the histology of the cells.

PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 6 months.

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS: Diagnosis of abnormal Pap test, as indicated by one of the following: Atypical squamous cells of undetermined significance (ASCUS) Low grade squamous intraepithelial lesion (LGSIL) High grade squamous intraepithelial lesion (HGSIL) Visible lesion on cervix by colposcopy

PATIENT CHARACTERISTICS: Age: Any age Performance status: ECOG 0-4 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Pregnant or nursing women allowed

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior pelvic irradiation Surgery: No prior total hysterectomy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004091

Locations


United States, Illinois
	Robert H. Lurie Comprehensive Cancer Center, Northwestern University
	Chicago, Illinois, United States, 60611-3013

Sponsors and Collaborators

Robert H. Lurie Cancer Center

National Cancer Institute (NCI)

Investigators


Study Chair:	Phillip Y. Roland, MD	Florida Gynecologic Oncology - Fort Myers

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000067304, NU-99G3, NCI-G99-1582
First Received:	December 10, 1999
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00004091
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

cervical cancer

Study placed in the following topic categories:

Genital Diseases, Female

Uterine Cervical Neoplasms

Antibodies

Uterine Cervical Diseases

Genital Neoplasms, Female

Uterine Diseases

Uterine Neoplasms

Urogenital Neoplasms

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

Immunologic Factors

Physiological Effects of Drugs

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsors and Collaborators:	Robert H. Lurie Cancer Center National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00004091